e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Asthma management IV
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The
in vitro
fine particle dose with Symbicort Rapihaler pMDI is similar using either NebuChamber or AeroChamber Plus valved holding chamber spacer devices
F. Chambers, E. Berg, M. Brown, J. O. Svensson (Loughborough, United Kingdom; Lund, Sweden)
Source:
Annual Congress 2005 - Asthma management IV
Session:
Asthma management IV
Session type:
Thematic Poster Session
Number:
3291
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Chambers, E. Berg, M. Brown, J. O. Svensson (Loughborough, United Kingdom; Lund, Sweden). The
in vitro
fine particle dose with Symbicort Rapihaler pMDI is similar using either NebuChamber or AeroChamber Plus valved holding chamber spacer devices. Eur Respir J 2005; 26: Suppl. 49, 3291
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
In vitro evaluation of spacers in comparison with T-adapters in mechanical ventilation with pressurized metered dose inhalers (pMDI) and vibrating mesh nebulizer.
Source: International Congress 2019 – COPD and other specific entities in intensive care unit medicine
Year: 2019
In vitro aerosol delivery by vibrating mesh nebulizer (VMN) and pressurized metered dose inhaler (pMDI) using spacers in comparison with T adapters in mechanical ventilation.
Source: Respiratory Failure and Mechanical Ventilation Conference 2020
Year: 2020
In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011
In vitro comparison of aerosol characteristics of HFA ipratropium bromide pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Assessment of the suitability of filters for use in clinical studies with an HFA fluticasone propionate pressurized metered dose inhaler (pMDI) and a valved holding chamber (VHC)
Source: Annual Congress 2011 - Lung function today and tomorrow II
Year: 2011
In vitro performance of a small non-electrostatic valved holding chamber made from metal with three different brands of pressurized metered dose inhalers
Source: Eur Respir J 2006; 28: Suppl. 50, 712s
Year: 2006
Impact of inhalation delay on medication delivery from a salbutamol HFA pressurized metered dose inhaler used with and without a new prototype portable valved holding chamber
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019
Valved holding chamber (VHC) angle can affect pressurized netered-dose inhaler (pMDI) medication delivery efficiency
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018
A novel breath-actuated vortex spacer device increases respirable dose delivery of fluticasone/salmeterol in combination
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
In vitro
equivalence exists for infant non-conducting (NC) and anti-static (AS) valved holding chambers (VHC) from the same family of add on devices used with pressurized metered dose inhalers (pMDIs) provided pre-conditioning of the non-conducting VHCs is undertaken
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation
Source: Eur Respir J 2001; 18: Suppl. 33, 102s
Year: 2001
Device handling study of a novel breath-actuated inhaler Synchrobreathe vs pMDI
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019
In vitro
comparison of output and particle size distribution of budesonide from metered-dose inhaler with three spacer devices during pediatric tidal breathing
Source: Eur Respir J 2005; 26: Suppl. 49, 161s
Year: 2005
Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Aerosol characterization of three corticosteroids in MDIs plus a new spacer device (Fluspacer®) vs MDIs alone
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001
Pressurized Metered Dose Inhaler (pMDI) with holding chamber - Correct procedure
Source: Procedure Video 2018
Year: 2018
In vitro testing of an improved collapsible valved holding chamber (CHC) with a pressurized metered-dose inhaler delivered bronchodilator, simulating an adult mechanically ventilated patient
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
In vitro
comparison of Pulmicort Respules™ with Clenil® pro aerosol in combination with three nebulisers
Source: Eur Respir J 2002; 20: Suppl. 38, 41s
Year: 2002
Flutide™ Diskus™ less consistent than Pulmicort® Turbuhaler® with respect to
in vitro
fine particle dose proportionality
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001
In vitro evaluation of a new spacer for pMDI and nebulizers in mechanical ventilation
Source: Annual Congress 2012 - Multidisciplinary critical care
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept